Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Non-current Assets
All assets not expected to be converted to cash within one year.
Citius Oncology, Inc.NASDAQ: CTOR
Total Non-current Assets · Q2 FY2026 · quarter ended Mar 2026
Total non-current assets falls 2.9% from a year ago
Total non-current assets stood at $71.28M at the end of Q2 FY2026, down 2.9% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Total non-current assets amounted to 70.8% of total assets at the end of Q2 FY2026, down 9.5 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -2.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 73.4M USD
- Year-over-year change
- +0.0%
- 3-year CAGR
- +22.4%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 73.4M | +0.0% |
| FY2024 | 2024-09-30 | 73.4M | +83.5% |
| FY2023 | 2023-09-30 | 40M | +0.0% |
| FY2022 | 2022-09-30 | 40M | — |
Total Non-current Assets vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total non-current assets of $71.28M is the 4th highest of the 10 companies compared; the peer median is $5.97M.
- Its year-over-year change of -2.9% is the 6th highest of 10, against a peer median of +0.2%.
- Total non-current assets amounts to 70.8% of total assets for CTOR, versus a peer median of 5.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $251.67M | +400.6% | +79.0% | 85.7% | |
| Mar 2026 | $105.39M | -30.0% | -18.5% | 37.0% | |
| Mar 2026 | $85.78M | -12.6% | -16.8% | 72.9% | |
CTORCitius Oncology, Inc. | Mar 2026 | $71.28M | -2.9% | +22.4% | 70.8% |
| Mar 2026 | $23.82M | +0.2% | +3.7% | 36.0% | |
| Mar 2026 | $5.97M | -86.6% | -54.1% | 1.2% | |
| Mar 2026 | $4.31M | +44.4% | -18.5% | 5.0% | |
| Mar 2026 | $2.11M | +602.0% | +65.2% | 3.1% | |
| Mar 2026 | $1.41M | -53.0% | -53.0% | 2.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $391.84K | +67.1% | — | 4.4% |
| Peer median (excluding CTOR) | $5.97M | +0.2% | -17.6% | 5.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.